Page 6 - தலை ஆஃப் உலகளாவிய ப்ராடக்ட் வளர்ச்சி News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Roche: Phase III Tecentriq Trial Shows Positive Results In Adjuvant Lung Cancer Setting
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Press Release : Pivotal Phase III data at ASCO show Roche s Tecentriq helps certain people with early lung cancer live significantly longer without their disease returning
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.
(0)
Tecentriq significantly improved overall survival in people with high PD-L1 expression, compared with chemotherapy in a Phase III study
Tecentriq
This approval marks
Tecentriq s fourth indication in metastatic non-small cell lung cancer and fifth indication in lung cancer overall in the EU
Basel, 5 May 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has approved Tecentriq (atezolizumab) as a first-line (initial) treatment for adults with metastatic non-small cell lung cancer (NSCLC) whose tumours have high PD-L1 expression , with no epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) genomic tumour aberrations. We are delighted to bring Tecentriq to people in the EU with this specific type of lung cancer, said Levi Garraway, M.D., Ph.D., Roche s Chief Medical Officer and Head of Global Product Development. Tecentriq monotherapy has been shown to improve overall survival in people with high PD-L1 expressi
Message :
Required fields Tecentriq significantly improved overall survival in people with high PD-L1 expression, compared with chemotherapy in a Phase III study Tecentriq approval offers an alternative to chemotherapy for all eligible patients This approval marks Tecentriq s fourth indication in metastatic non-small cell lung cancer and fifth indication in lung cancer overall in the EU Basel, 5 May 2021 Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced
that the European Commission has approved Tecentriq(R) (atezolizumab) as
a first-line (initial) treatment for adults with metastatic non-small
cell lung cancer (NSCLC) whose tumours have high PD-L1 expression , with
no epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase
Roche: EU Approves Tecentriq For People With Specific Type Of Lung Cancer
SOUTH SAN FRANCISCO (dpa-AFX) - Swiss drug major Roche (RHHBY) announced Wednesday that the European Commission has approved Tecentriq (atezolizumab) for people with specific type of lung cancer.
Tecentriq has been approved as a first-line (initial) treatment for adults with metastatic non-small cell lung cancer or NSCLC whose tumours have high PD-L1 expression, with no epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) genomic tumour aberrations.
Roche noted that Tecentriq is now the first and only single-agent cancer immunotherapy with three dosing options, allowing administration every two, three or four weeks. This gives physicians and patients greater flexibility on how they manage their treatment.
vimarsana © 2020. All Rights Reserved.